(Q52813540)

English

Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.

scientific article published on 13 December 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

1 reference

based on heuristic

inferred from title

chronic idiopathic myelofibrosis

1 reference

based on heuristic

inferred from title

author name string

Thamer Sliwa

1

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Christine Beham-Schmid

2

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Sonja Burgstaller

3

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Veronika Buxhofer-Ausch

4

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Günther Gastl

5

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Klaus Geissler

6

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Maria Krauth

7

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Peter Krippl

8

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Alois Lang

9

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Andreas Petzer

10

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Stefan Wöhrer

11

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Albert Wölfler

12

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Heinz Gisslinger

13

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

publication date

13 December 2016

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Vienna Clinical Weekly

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

129

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

9-10

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

293-302

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

The role of cytokines in the initiation and progression of myelofibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Somatic mutations of calreticulin in myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

A comprehensive review of pacritinib in myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

The role of interferon-alpha in the treatment of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Disseminated tuberculosis associated with ruxolitinib.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypercalcemia and adrenal insufficiency in a patient with myelofibrosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00508-016-1120-8

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27966016

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52813540&oldid=2211870144"